Chengcheng Meng

Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy

Wei Ni, Swati Garg, Basudev Chowdhury, Martin Sattler et autres

[This corrects the article DOI: 10.1016/j.omton.2025.200952.].

Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy

Wei Ni, Swati Garg, Basudev Chowdhury, Martin Sattler et autres

Advancements in the treatment of multiple myeloma (MM) have resulted in an improvement in the survival rate. However, there continues to be an urgent need for improved therapies. The protein arginine methyltransferase, CARM1 (coactivator associated arginine methyltransferase 1), is emerging as a …

us (code pays fourni par la source)

Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8

Yufeng Xiao, Nikee Awasthee, Yi Liu, Chengcheng Meng et autres

HDAC8 plays crucial roles in biological processes, from gene regulation to cell motility, making it a highly desirable target for therapeutic intervention. HDAC8 also has deacetylase-independent activity which cannot be blocked by a conventional inhibitor. In this study, we report the discovery …

us, ca (code pays fourni par la source)

Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma

Basudev Chowdhury, Swati Garg, Wei Ni, Martin Sattler et autres

Progress in the treatment of multiple myeloma (MM) has resulted in improvement in the survival rate. However, there is still a need for more efficacious and tolerated therapies. We and others have shown that bromodomain-containing protein 9 (BRD9), a member of the …

us, ch (code pays fourni par la source)

Abstract 3236: Discovery of hydrazide-based HDAC8 selective PROTACs

Yufeng Xiao, Yi Liu, Nikee Awasthee, Chengcheng Meng et autres

Abstract HDAC8 plays crucial roles in biological processes and is a highly desirable target for therapeutic interventions. However, due to the conserved catalytic domain among HDACs, developing specific inhibitors for these isozymes has proven challenging. HDAC8 also has deacetylase-independent activity which cannot …

us, ca (code pays fourni par la source)

HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation

Yufeng Xiao, Seth M. Hale, Nikee Awasthee, Chengcheng Meng et autres

us (code pays fourni par la source)

DAXX drives de novo lipogenesis and contributes to tumorigenesis

Iqbal Mahmud, Guimei Tian, Jia Wang, Tarun Edgar Hutchinson et autres

Cancer cells exhibit elevated lipid synthesis. In breast and other cancer types, genes involved in lipid production are highly upregulated, but the mechanisms that control their expression remain poorly understood. Using integrated transcriptomic, lipidomic, and molecular studies, here we report that DAXX …

us, cn (code pays fourni par la source)

Anti‐SARS‐CoV‐2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID‐19 therapy

RuthMabel Boytz, Mikolaj Michal Slabicki, Sita Ramaswamy, Justin J. Patten et autres

Coronavirus disease 2019 (COVID-19) remains a major public health concern, and vaccine unavailability, hesitancy, or failure underscore the need for discovery of efficacious antiviral drug therapies. Numerous approved drugs target protein kinases associated with viral life cycle and symptoms of infection. Repurposing …

us (code pays fourni par la source)

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

Ellen Weisberg, Basudev Chowdhury, Chengcheng Meng, Abigail E. Case et autres

Bromodomain-containing protein 9 (BRD9), an essential component of the SWI/SNF chromatin remodeling complex termed ncBAF, has been established as a therapeutic target in a subset of sarcomas and leukemias. Here, we used novel small molecule inhibitors and degraders along with RNA interference …

us, ch (code pays fourni par la source)

Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2

Jing Chun Yang, Ellen Weisberg, Shuang Qi, Wei Ni et autres

us, cn (code pays fourni par la source)

Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2

Jing Chun Yang, Ellen Weisberg, Xiaoxi Liu, Robert S. Magin et autres

us (code pays fourni par la source)

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)

Moshe Lapidot, Abigail E. Case, Ellen Weisberg, Chengcheng Meng et autres

BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with a dismal prognosis. There is increasing interest in targeting chromatin regulatory pathways in difficult-to-treat cancers. In preliminary studies, we found that KDM4A (lysine-specific histone demethylase 4) was overexpressed in MPM. METHODS: …

us, at (code pays fourni par la source)